The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| TMDX | +49.95% | +871.58% | +57.58% | +457% |
| S&P | +17.53% | +93.66% | +14.13% | +133% |
TransMedics Group, Inc. operates as a commercial stage medical technology company. The firm engages in the development and commercialization of organ care system platform. It focuses on the preservation of human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation. The company was founded by Waleed H. Hassanein in August 1998 and is headquartered in Andover, MA.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $143.82M | 32.2% |
| Gross Profit | $84.48M | 39.1% |
| Gross Margin | 58.74% | 2.9% |
| Market Cap | $3.82B | -27.0% |
| Market Cap / Employee | $5.25M | 0.0% |
| Employees | 728 | 24.7% |
| Net Income | $24.32M | 476.8% |
| EBITDA | $30.15M | 231.3% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $466.17M | 41.2% |
| Accounts Receivable | $80.70M | -10.5% |
| Inventory | 44.5 | -14.7% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $511.11M | -0.9% |
| Short Term Debt | $8.24M | 223.9% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 10.60% | 6.2% |
| Return On Invested Capital | -14.74% | 8.5% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $61.95M | 249.8% |
| Operating Free Cash Flow | $69.57M | 914.6% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 61.72 | 49.45 | 69.30 | 45.32 | -73.06% |
| Price to Book | 9.97 | 9.89 | 17.02 | 12.01 | -52.17% |
| Price to Sales | 4.97 | 5.50 | 10.23 | 8.07 | -42.21% |
| Price to Tangible Book Value | 10.67 | 10.52 | 17.94 | 12.54 | -53.30% |
| Price to Free Cash Flow TTM | 313.24 | 37.90 | - | ||
| Enterprise Value to EBITDA | 165.95 | 86.17 | 128.26 | 153.41 | -75.89% |
| Free Cash Flow Yield | 0.3% | 2.6% | - | ||
| Return on Equity | 19.4% | 23.0% | 28.2% | 32.5% | 67.36% |
| Total Debt | $518.29M | $518.41M | $518.82M | $519.35M | 0.23% |
TMDX earnings call for the period ending September 30, 2020.
TMDX earnings call for the period ending June 30, 2020.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
